Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes

MLA

Peter A. E. Sillevis Smitt, et al. Phase II Trial of Natalizumab for the Treatment of Anti-Hu Associated Paraneoplastic Neurological Syndromes. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3de9e91684ea9ce38b00204e31174adf&authtype=sso&custid=ns315887.

APA

Peter A. E. Sillevis Smitt, Marienke A.A.M. de Bruijn, Yvette S Crijnen, Walter Taal, Marcel M. Verbeek, Maarten J. Titulaer, Marco W.J. Schreurs, Adriaan H.C. de Jongste, Daphne W. Dumoulin, & Anna E M Bastiaansen. (2021). Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

Chicago

Peter A. E. Sillevis Smitt, Marienke A.A.M. de Bruijn, Yvette S Crijnen, Walter Taal, Marcel M. Verbeek, Maarten J. Titulaer, Marco W.J. Schreurs, Adriaan H.C. de Jongste, Daphne W. Dumoulin, and Anna E M Bastiaansen. 2021. “Phase II Trial of Natalizumab for the Treatment of Anti-Hu Associated Paraneoplastic Neurological Syndromes,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3de9e91684ea9ce38b00204e31174adf&authtype=sso&custid=ns315887.